Diurnal inks distribution agreement with Vector Pharma

Pharmaceutical company Diurnal has inked a distribution agreement with Vector Pharma for its Alkindi asset across the Middle East and North Africa.

Diurnal said on Wednesday that its exclusive partnership with Vector will see the latter receive the exclusive rights to distribute Alkindi in Morocco, Tunisia, Algeria, Libya, Egypt, Saudi Arabia, Qatar, United Arab Emirates, Bahrain, Kuwait, Oman, Lebanon, Jordan, and Iraq.

The AIM-listed firm stated that through Vector, Alkindi will be available to paediatric patients who qualify through applicable early access programmes for patients with diseases of cortisol deficiency who have no other treatment options.

The distribution agreement will further extend the global rollout of Alkindi, which has already received approval in the UK, European Economic Area, Israel, Australia, and the US.

Chief executive Martin Whitaker said: "We are pleased to be working with Vector Pharma to extend the availability of Alkindi to a large geographic region where there is a significant unmet patient need in children suffering from AI and CAH.

"Working with Vector Pharma will further broaden the future availability of Alkindi outside of our core markets and we believe that Vector Pharma is well-positioned to distribute Alkindi across the 14 counties in this agreement and to ensure it reaches key healthcare providers and patients."

As of 0855 BST, Diurnal shares were down 0.19% at 15.87p.